However, in our hands, we did not observed any change in the expression of stemness markers upon PGE2 treatment in glioma primary cultures regardless of the molecular sub-class of GBM and independently of the proportion of CD133+ cells. The gene discussed is PROM1; the disease is glioblastoma.